Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
Evotec SE (NASDAQ:EVO) has achieved a significant milestone in its neuroscience collaboration with Bristol Myers Squibb, triggering a $20 million research payment. The achievement relates to advancing a promising pre-clinical programme in neurodegeneration.
The strategic partnership, initiated in December 2016, focuses on developing disease-modifying treatments for neurodegenerative diseases, moving beyond current symptom management approaches. Notable successes include the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021.
In March 2023, both companies extended their collaboration for an additional eight years, demonstrating their commitment to developing breakthrough therapies for neurological diseases.
Evotec SE (NASDAQ:EVO) ha raggiunto un traguardo significativo nella sua collaborazione nel campo delle neuroscienze con Bristol Myers Squibb, attivando un pagamento per la ricerca di 20 milioni di dollari. Questo risultato è legato all'avanzamento di un promettente programma preclinico nella neurodegenerazione.
La partnership strategica, avviata nel dicembre 2016, si concentra sullo sviluppo di trattamenti modificanti la malattia per le malattie neurodegenerative, andando oltre gli attuali approcci di gestione dei sintomi. Tra i successi notevoli c'è l'in-licensing di EVT8683 (ora BMS-986419) da parte di Bristol Myers Squibb nel settembre 2021.
Nel marzo 2023, entrambe le aziende hanno esteso la loro collaborazione per ulteriori otto anni, dimostrando il loro impegno nello sviluppo di terapie innovative per le malattie neurologiche.
Evotec SE (NASDAQ:EVO) ha logrado un hito significativo en su colaboración en neurociencia con Bristol Myers Squibb, activando un pago de investigación de 20 millones de dólares. Este logro está relacionado con el avance de un prometedor programa preclínico en neurodegeneración.
La asociación estratégica, iniciada en diciembre de 2016, se centra en el desarrollo de tratamientos modificadores de la enfermedad para enfermedades neurodegenerativas, y va más allá de los enfoques actuales de manejo de síntomas. Entre los éxitos notables se encuentra la concesión de licencia de EVT8683 (ahora BMS-986419) a Bristol Myers Squibb en septiembre de 2021.
En marzo de 2023, ambas compañías extendieron su colaboración por ocho años adicionales, demostrando su compromiso con el desarrollo de terapias innovadoras para enfermedades neurológicas.
Evotec SE (NASDAQ:EVO)는 Bristol Myers Squibb와의 신경과학 협력에서 중요한 이정표를 달성하여 2천만 달러의 연구 비용을 촉발했습니다. 이 성과는 신경퇴행에 관한 유망한 전임상 프로그램의 발전과 관련이 있습니다.
2016년 12월에 시작된 이 전략적 파트너십은 신경퇴행성 질환에 대한 질병 수정 치료제를 개발하는 데 중점을 두고 있으며, 현재의 증상 관리 접근 방식을 넘어섭니다. 주목할 만한 성공으로는 2021년 9월 Bristol Myers Squibb에 의해 EVT8683(현재 BMS-986419)의 라이센스가 있습니다.
2023년 3월, 양사는 신경 질환에 대한 혁신적인 치료제를 개발하기 위한 헌신을 보여주며 협력을 8년 더 연장했습니다.
Evotec SE (NASDAQ:EVO) a atteint un jalon significatif dans sa collaboration en neurosciences avec Bristol Myers Squibb, déclenchant un paiement de recherche de 20 millions de dollars. Cette réalisation est liée à l'avancement d'un programme préclinique prometteur en neurodégénérescence.
Le partenariat stratégique, initié en décembre 2016, se concentre sur le développement de traitements modifiant la maladie pour les maladies neurodégénératives, allant au-delà des approches actuelles de gestion des symptômes. Parmi les succès notables, on trouve l'octroi de licence d'EVT8683 (maintenant BMS-986419) par Bristol Myers Squibb en septembre 2021.
En mars 2023, les deux entreprises ont prolongé leur collaboration de huit années supplémentaires, démontrant leur engagement à développer des thérapies novatrices pour les maladies neurologiques.
Evotec SE (NASDAQ:EVO) hat einen bedeutenden Meilenstein in seiner Zusammenarbeit im Bereich Neurowissenschaften mit Bristol Myers Squibb erreicht und einen Forschungszahlung von 20 Millionen Dollar ausgelöst. Dieser Erfolg steht im Zusammenhang mit dem Fortschritt eines vielversprechenden präklinischen Programms zur Neurodegeneration.
Die strategische Partnerschaft, die im Dezember 2016 ins Leben gerufen wurde, konzentriert sich auf die Entwicklung von krankheitsmodifizierenden Behandlungen für neurodegenerative Erkrankungen und geht über die derzeitigen Symptommanagementansätze hinaus. Zu den bemerkenswerten Erfolgen gehört die Lizenzierung von EVT8683 (jetzt BMS-986419) durch Bristol Myers Squibb im September 2021.
Im März 2023 verlängerten beide Unternehmen ihre Zusammenarbeit um weitere acht Jahre, was ihr Engagement für die Entwicklung bahnbrechender Therapien für neurologische Erkrankungen unter Beweis stellt.
- Received $20M research payment from Bristol Myers Squibb
- Successful advancement of pre-clinical program in neurodegeneration
- Long-term partnership extension secured (additional 8 years)
- Previous success with EVT8683 in-licensing deal
- None.
Ongoing strategic partnership advances joint pipeline in neurodegeneration research
Evotec receives a
$20 million payment to further progress research
HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced another major accomplishment in its long-standing neuroscience collaboration with Bristol Myers Squibb (NYSE: BMY). The latest scientific achievement in the partnership has triggered a research payment of US
Since the initiation of their strategic neuroscience collaboration in December 2016, Evotec and Bristol Myers Squibb have been working together to identify disease-modifying treatments for a broad range of neurodegenerative diseases. While currently approved therapies primarily focus on symptom management, this partnership aims to develop transformative treatments that can slow or halt disease progression - addressing a significant unmet medical need.
The collaboration has already yielded strong results, including the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021. In March 2023, the companies reaffirmed their commitment by extending and expanding the collaboration for an additional eight years.
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, commented:
"This latest achievement further underscores the strength of our collaboration with Bristol Myers Squibb and the impact it has for jointly building a strong pipeline in neurological diseases. Our continued success highlights the unique commitment and reinforces our shared mission to deliver truly innovative treatment options for patients suffering from neurodegenerative diseases. With another high-potential program advancing towards clinical development, we are taking yet another important step in our pursuit of breakthrough therapies."
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
Media
Susanne Kreuter
VP Head of Strategic Marketing
Susanne.Kreuter@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire
FAQ
What milestone did Evotec (EVO) achieve in its collaboration with Bristol Myers Squibb?
How long has Evotec (EVO) been collaborating with Bristol Myers Squibb in neuroscience?
What was the previous major milestone in Evotec's (EVO) collaboration with Bristol Myers Squibb?
When was Evotec's (EVO) collaboration with Bristol Myers Squibb extended, and for how long?
